Sepsis research honoured
Germany - The third Hugo Schottmüller Prize, awarded by the German Sepsis Society (DSG), has been presented to Dr Marc W Merx, of the Rheinisch-Westfälische Technical University (RWTH) Hospital, Aachen, for his paper ‘HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of Sepsis’, published in the journal Circulation.
The DSG reported that Dr Merx and colleagues had described a promising starting point for a new sepsis therapy. They reported that the drug Simvastatin, which lowers blood cholesterol levels, increased the survival rate of mice suffering sepsis. Dr Merx’ work is a starting point for further investigations on a Simvastatin-based therapy for inflammation-related diseases.
Worth 3,000 euros, the DSG’s research prize is funded by SIRS-Lab GmbH.
This article was published on 03/01/2005
Search
Service
Company News
Accu-Chek® Combo – put effective diabetes management into action
At the annual congress of the European Association for the Study of Diabetes (EASD) this year in Rome, Roche Diabetes Care introduced Accu-Chek Combo – the insulin pump system that combines an insulin pump with an intelligent glucose monitoring system, a bolus calculator, and an integrated pump remote-control.
Carestream: technical infrastructure for EU funded R-bay project
Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.
Insulin in oral capsules
At the international congress on diabetes in September, Oramed Pharmaceuticals, Inc. introduced its oral insulin capsules that might in the future replace injections patients currently have to face. Last week Oramed announced the agreement with ETI Karle Clinical Pvt. Ltd. to conduct phase 2B clinical trials for its oral insulin capsules.
.jpg&contenttype=jpeg)
